Cipla USA recalled 1,180 boxes of Lanthanum Carbonate chewable tablets on October 24, 2025. The recall follows a failure to meet stability specifications for hardness tests. Consumers and healthcare providers must stop using the product immediately.
Failed stability specifications: Out of specification for hardness test
Consumers and healthcare providers should stop using this product immediately. Contact Cipla USA, Inc. or your healthcare provider for guidance. Notification method: N/A
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Lanthanum Carbonate chewable tablets are prescribed to manage phosphate levels in patients with kidney disease. They help reduce the risk of complications associated with high phosphate levels.
The recalled tablets did not meet stability specifications for hardness, which could impact their effectiveness as a treatment.
This recall is not part of a broader industry pattern.
Consumers should be aware that using ineffective medication could lead to health complications, necessitating immediate action.
The lot number and expiration date can typically be found on the bottom or side of the bottle.
Expect a refund or replacement processing time of 4-6 weeks after return.
Keep receipts and any correspondence with the manufacturer regarding the recall.
The recall includes Lanthanum Carbonate chewable tablets, 1000mg. The affected lot number is NB240315, with an expiration date of December 31, 2025. The product was distributed nationwide in the USA.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Cipla USA, Inc. recalls lanreotide acetate 120 mg/0.5 mL pre-filled syringes distributed nationwide due to lack of assurance of sterility after FDA observations at the contract manufacturer. Health care providers and patients should stop use immediately and contact Cipla or their clinician for guidance.
Cipla USA Inc. recalls 54,583 Lanreotide acetate injections nationwide after FDA flagged sterility assurance concerns at a contract manufacturer. The recall covers a box containing one pre-filled syringe and one safety needle. Healthcare providers and patients should stop using the product immediately and follow the company’s guidance for disposal and refunds.
Cipla USA, Inc. is recalling 15,221 Lanreotide Acetate Injection syringes nationwide in the United States after detecting particulate matter. The defect is the presence of particulate matter in the injectable solution. Healthcare providers and patients should stop using the product immediately and contact Cipla USA for guidance.
Cipla USA recalled 12,576 bottles of Cinacalcet Hydrochloride Tablets on November 14, 2025, due to a nitrosamine impurity. The impurity, N-nitroso-cinacalcet, exceeds acceptable daily intake limits. Consumers must stop using this product immediately and contact healthcare providers for guidance.
Cipla USA, Inc. recalled 15,744 bottles of Cinacalcet Hydrochloride Tablets on November 14, 2025. The recall follows the discovery of a nitrosamine impurity exceeding acceptable daily intake limits. Consumers should stop using the product immediately and consult healthcare providers.
Cipla USA, Inc. recalled 63,504 bottles of Cinacalcet Hydrochloride Tablets on November 14, 2025. The recall results from a nitrosamine impurity, N-nitroso-cinacalcet, exceeding acceptable daily intake limits. Consumers should stop using the tablets immediately and contact healthcare providers for guidance.
Cipla USA recalled 4,438 cartons of Phytonadione Injectable Emulsion on October 31, 2025. The product failed stability specifications, raising concerns about its safety. Consumers and healthcare providers must stop using the product immediately and seek guidance.
Invagen Pharmaceuticals recalled Lanthanum Carbonate chewable tablets on October 24, 2025, due to stability issues. The tablets failed hardness specifications, posing a high hazard level. Healthcare providers and consumers should stop using the product immediately.